Proteogenomic clues to NSCLC recurrence in early-stage lung cancer
Official title: Proteogenomic Predictors of Recurrence in Non-small Cell Lung Cancer
Funded at Washington University · NIH-11345500 · Data updated 2026-11-12
A national study will look at the tumor’s genetic and protein signals to find clues about which early-stage non-small cell lung cancer may come back after surgery.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | June 13, 2022 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,049,939 |
| NIH project number | 5U01CA271402-05 |
| Project ID | NIH-11345500 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with resected early-stage NSCLC (stage II-III) or those contributing samples to genomics analyses within the study framework.
✕Less likely to help
Patients not contributing tumor samples or data, or those without the identified biomarkers, may not directly benefit.
What this research studies
This project examines tumor DNA, RNA, and protein data from patients with early-stage NSCLC to identify markers associated with recurrence after complete tumor removal. It builds on prior trials that used targeted therapies and immune therapies in early disease and will leverage large, multi-center tumor samples to uncover patterns that predict poor outcomes. The study involves whole-genome, exome, and transcriptome analyses, and will integrate these data with clinical information to identify meaningful predictors. Participants would contribute tumor samples and clinical data, with findings potentially guiding future personalized treatment options.
Why it matters
Potential benefit: If successful, patients with early NSCLC could receive more accurate risk predictions and tailored follow-up or adjuvant therapies to reduce recurrence.
How similar studies have gone: Previous multi-center genomics efforts in lung cancer have identified markers; this study extends those findings to recurrence risk.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Govindan, Ramaswamy — Washington University
- Study coordinator: Govindan, Ramaswamy
Related research
Other NIH-funded projects on the same topics.
-
How air pollution and neighborhood stress affect lung tumors in African American patients
This project looks at whether long-term air pollution and neighborhood disadvantage change tumor DNA and short-term recurrence risk in early-stage lung cancer among African American patients.
-
Identifying genetic markers to predict lung cancer recurrence
This study is looking at the genes in early-stage non-small cell lung cancer to find clues that might help predict if the cancer will come back after surgery, and if you join, you could help improve future treatments for lung cancer.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.